TRPC1 and breast carcinoma: Compared to the non-targeting siRNA control, MDA-MB-468 breast cancer cells with TRPC1 silencing showed modest but significant reductions in cell number (Fig. 8C-DAPI and Fig. 8D) and a reduced percentage of cells in the S-phase of the cell cycle (Fig. 8C-EdU and Fig. 8E).